PARP inhibitor

DRUG8 trials

Sponsors

Hellenic Cooperative Oncology Group, University Hospital, Caen, Xiaoxiang Chen, Shanghai Gynecologic Oncology Group, Tianjin Medical University Cancer Institute and Hospital

Conditions

CancerFallopian Tube CancerFallopian Tube CancersHRDHigh Risk Prostate CancerIntense Endocrine TherapyLocally Advanced Prostate CancerLung Cancer

Phase 2

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

RecruitingNCT05200260

Shanghai Gynecologic Oncology GroupFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2022-07-13End: 2027-06-30Target: 220Updated: 2025-02-10

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and HospitalLung Cancer

Start: 2022-06-20End: 2025-04-01Target: 52Updated: 2022-05-26

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

RecruitingNCT05406999

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHigh Risk Prostate Cancer, Intense Endocrine Therapy, Locally Advanced Prostate Cancer +1

Start: 2020-02-01End: 2030-06-30Target: 900Updated: 2022-08-16

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

RecruitingNCT06145308

Peking Union Medical CollegePrecision Therapy, Salivary Gland Carcinoma

Start: 2023-08-15End: 2028-07-10Target: 39Updated: 2026-04-02

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

RecruitingNCT07472140

N.N. Alexandrov National Cancer CentreFallopian Tube Cancers, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-07-01End: 2033-06-30Target: 120Updated: 2026-03-16

Unknown Phase

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Hellenic Cooperative Oncology GroupOvarian Cancer

Start: 2019-11-01End: 2023-09-30Target: 150Updated: 2023-03-14

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

CompletedNCT04774627

University Hospital, CaenCancer

Start: 2021-02-07End: 2021-03-24Updated: 2021-09-23

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Xiaoxiang ChenHRD, Ovarian Cancer, PARP Inhibitor

Start: 2021-09-15End: 2023-09-30Target: 100Updated: 2021-09-14

Related Papers

Anti-TROP2 ADC ESG401 in a master protocol clinical trial for salivary gland cancer based on molecular typing.

Journal of Clinical Oncology2025-05-28

A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery

Frontiers in Oncology2023-01-13